Reverse Innovation And Localization To Reduce Costs For Device Players: China Healthcare Investment Conference
This article was originally published in PharmAsia News
Executive Summary
Medtronic, Mindray and Lepu fill different niches, and executives discussed opportunities to build off of each other at a recent Shanghai conference.
You may also be interested in...
Medical Device Companies Come Up With Creative Solutions To Increase Access To Rural Communities In Asia
HONG KONG - A little less than two years ago, multinational conglomerate GE Healthcare said it would spend up to $6 billion in healthcare innovation through a program dubbed "Healthymagination.
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.